| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 30 May 2026 | 26 May 2026 |
| To consider and approve the financial results for the period ended March 31, 2026 Curis Lifesciences Limited has informed the Exchange regarding Outcome of Board Meeting held on May 30, 2026 regarding considering and approving the Audited Standalone Financial Results of the company for the half year and year ended on March 31, 2026. (As Per NSE Announcement Dated on : 30.05.2026) | ||
| Board Meeting | 28 Mar 2026 | 30 Mar 2026 |
| Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 we wish to inform that, the Board of Directors of the Company at its meeting held on Saturday, 28th March 2026 | ||
| Board Meeting | 24 Dec 2025 | 25 Dec 2025 |
| Curis Lifesciences Limited has informed the Exchange about Agreements. | ||
| Board Meeting | 4 Dec 2025 | 28 Nov 2025 |
| To consider and approve the financial results for the period ended September 30, 2025. Curis Lifesciences Limited has submitted to the Exchange, the financial results for the period ended September 30, 2025. (As Per NSE Announcement Dated on : 05/12/2025) | ||
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.